ValueScreener company report

BioHarvest Sciences Inc. Common Stock (BHST)

Name: BioHarvest Sciences Inc. Common Stock (BHST) filed financial figures
Creator: ValueScreener

NASDAQ / Basic Materials / Agricultural Inputs

Share price

1.70 USD Market dataClose of Oct 15, 2026

Market capitalisation

29.5M USD Market dataClose of Oct 15, 2026

Market data: Oct 15, 2026
Filed accounts: FY2025, filed Mar 31, 2026
Ratios computed: Oct 15, 2026
Filed years: 3, FY2023 to FY2025

Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means

SEC filingFiled with the SEC: Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement: What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data: Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener: Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.

Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Quality

Return on invested capital, after tax

n/a Computed

From the FY2025 filing

Why n/a

No annual statement of this kind is on file for this fiscal year.

Read quality

Financial strength

Debt to equity

n/a Computed

Why n/a

No annual statement of this kind is on file for this fiscal year.

Read financial strength

Valuation

Price to earnings

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

Read valuation

Cash generation

Free cash flow yield

-32.5% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

Revenue Net income10 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.

Named tests met: 0 of 30 Which tests

The business, and the score behind its five axes

The reading, in brief

Is it cheap

Free cash flow yield is -32.5% at the close of 2026-10-15 on FY2025 figures; the lines are 2.0%, 5.0% and 8.0%, set by convention, and this sits below the lowest.

Today, against the Basic Materials sector (220 companies), -32.5% sits at the 9th percentile; the middle half of that group runs from -7.0% to 4.4%.

Is it good

Operating margin was -16.2% in FY2025. No published threshold exists for operating margin, so its standing against peers is the reading.

Today, against the Basic Materials sector (171 companies), -16.2% sits at the 20th percentile; the middle half of that group runs from -7.8% to 19.9%.

Is it safe

Interest coverage for BioHarvest Sciences Inc. Common Stock in FY2025: n/a. No interest expense is filed for this year, so coverage is not computed.

Year by year against peers: Whether BioHarvest Sciences Inc. Common Stock's operating margin stayed above the median of the Basic Materials sector, year by year. (FY2020 to FY2025, 6 fiscal years of BioHarvest Sciences Inc. Common Stock with a comparable figure)
What could explain it: What in BioHarvest Sciences Inc. Common Stock's filed statements could explain the movements. (2 readings drawn from the statement lines BioHarvest Sciences Inc. Common Stock filed)
What to check next: What to check next on BioHarvest Sciences Inc. Common Stock, and where in its filings. (3 questions for BioHarvest Sciences Inc. Common Stock)
In one paragraph: One paragraph on BioHarvest Sciences Inc. Common Stock's returns, cash, balance sheet and price. (5 of sixteen figures read for BioHarvest Sciences Inc. Common Stock)

These are BHST’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research BHSTPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 40-F, filed Mar 31, 2026, accession 0001376474-26-000257.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

BioHarvest Sciences Inc. Common Stock: returns on capital and margins, each with its source
Figure	Value, source and document
Return on invested capital, after tax Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Return on equity Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Return on capital employed, pre-tax Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Return on assets Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Gross margin	59.3% ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Operating margin	-16.2% ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Net margin	-32.3% ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257

BHST -32.3%

-58.4%8.6%

Net margin: BHST against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

Market dataComputedCompany statement

BioHarvest Sciences Inc. Common Stock: leverage, liquidity and distress, each with its source
Figure	Value, source and document
Debt to equity Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedStatement not held
Current ratio Why n/a No annual statement of this kind is on file for this fiscal year.	n/a ComputedStatement not held
Quick ratio Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Interest coverage Why n/a No interest expense is filed for this year, so coverage is not computed.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Altman Z-score Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Net debt	8.8M ComputedFY2022 market data, supplied Oct 15, 2026, no SEC filing named, accession n/a

Total assets Total liabilities Shareholders’ equity (zero or below, not drawn)

The balance sheet, line by line

Financial health

What BioHarvest Sciences Inc. Common Stock owned and owed at the end of fiscal 2022, from a copy of its balance sheet that names no SEC filing (market data).

BioHarvest Sciences Inc. Common Stock: balance sheet position
Total assets	9.4M Market dataFY2022 market data, supplied Oct 15, 2026, no SEC filing named
Total liabilities	15.3M Market dataFY2022 market data, supplied Oct 15, 2026, no SEC filing named
Shareholders' equity	-5.9M Market dataFY2022 market data, supplied Oct 15, 2026, no SEC filing named
Cash	1.7M Market dataFY2022 market data, supplied Oct 15, 2026, no SEC filing named
Total debt	10.6M Market dataFY2022 market data, supplied Oct 15, 2026, no SEC filing named
Net debt	8.8M
Current ratio	n/a
Debt to equity	n/a

Debt to equity: FY2022: The figures on this page are FY2025's, and for FY2025 this ratio is n/a; this FY2022 figure is from another year's balance sheet, so it is not printed beside them.
Current ratio: FY2022: The figures on this page are FY2025's, and for FY2025 this ratio is n/a; this FY2022 figure is from another year's balance sheet, so it is not printed beside them.
Interest cover: FY2022: The figures on this page are FY2025's, and for FY2025 this ratio is n/a; this FY2022 figure is from another year's balance sheet, so it is not printed beside them.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

BioHarvest Sciences Inc. Common Stock: what the market charges, each with its source
Figure	Value, source and document
Price to earnings Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
P/E on trailing twelve months Why n/a A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.	n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · Statement not held
Price to sales	0.85x ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Enterprise value to EBIT Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Enterprise value to EBITDA Why n/m EBITDA is zero or negative, so a multiple of it is not meaningful.	n/m ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Price to earnings over growth Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Diluted earnings per share Why n/a The FY2025 filing carries no diluted earnings per share we could read.	n/a FiledFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Graham number Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257

We publish no fair value or price target of our own. Value BHST on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for BioHarvest Sciences Inc. Common Stock today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

BioHarvest Sciences Inc. Common Stock: valuation
Share price	1.70 USD
Market capitalisation	29.5M USD
Enterprise value to EBITDA	n/m
Graham number	n/m
Diluted earnings per share, FY2022	n/a

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like BioHarvest Sciences Inc. Common Stock

Same industry (Agricultural Inputs) and size band (Nano, under 50M), nearest in market value and net margin. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

BioHarvest Sciences Inc. Common Stock: cash generation and what is paid out, each with its source
Figure	Value, source and document
Free cash flow yield	-32.5% ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Free cash flow	-9.6M USD ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Free cash flow margin	-27.8% ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Dividend yield Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Payout ratio Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257

Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

BioHarvest Sciences Inc. Common Stock: the eight ratios, with the fiscal year and filing date behind each.
Figure	Value	Year	As of
	n/m	FY2025	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaShare price / earnings per share. Where the filing states no earnings per share this listing can be priced on, which is every 20-F and 40-F filer because theirs is stated per ordinary share, it is market capitalisation / net income: the same multiple, undiluted. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	n/a	Oct 15, 2026
n/a No balance sheet for the latest filed year is on file, or the one on file reports no total assets.
FormulaMarket capitalisation / shareholders equity As ofThe close on Oct 15, 2026, over the filed figures of n/a: a price is in this figure, and it moved after the filing.
	n/a	FY2025	Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
Formula(Market capitalisation + total debt - cash) / operating income, or over the filing's own EBIT (income before tax + interest expense) where the filer tags no operating line, as Johnson & Johnson does not in any of its ten filed years. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	-32.5%	FY2025	Oct 15, 2026
FormulaFree cash flow per share / share price x 100 As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	FY2025	Mar 31, 2026
n/a No annual statement of this kind is on file for this fiscal year.
FormulaVendor trailing-twelve-month return on invested capital where one is published, which uses after-tax operating profit over total assets less current liabilities. Otherwise our own recompute: NOPAT / (shareholders equity + total debt - cash) x 100, where NOPAT is the filed operating profit after tax, or the filing's own EBIT after tax where the filer tags no operating line. As ofThe filing date of the statements below, for FY2025. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	FY2025	Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
FormulaCommon dividends paid in the latest filed year / market capitalisation x 100. n/a where the filing cannot support it: a special or first-year payment, a total that mixes preferred dividends, or a cash-flow statement over 15 months old. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	n/a	n/a
n/a No annual statement of this kind is on file for this fiscal year.
FormulaTotal debt / shareholders equity As ofThe filing date of the statements below.
	n/a	n/a	n/a
n/a No annual statement of this kind is on file for this fiscal year.
FormulaCurrent assets / current liabilities As ofThe filing date of the statements below.
	0.85x	FY2025	Oct 15, 2026
FormulaMarket capitalisation / revenue As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/m	FY2025	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaPrice to earnings / the annual earnings growth rate, in percentage points As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	FY2025	Oct 15, 2026
n/a No balance sheet for the latest filed year is on file, or the one on file reports no total assets.
Formula1.2 x working capital/assets + 1.4 x retained earnings/assets + 3.3 x EBIT/assets + 0.6 x market value of equity/total liabilities + 1.0 x revenue/assets As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	FY2025	Mar 31, 2026
n/a No balance sheet for the latest filed year is on file, or the one on file reports no total assets.
FormulaAn eight-variable index of year-on-year changes in receivables, gross margin, asset quality, revenue, depreciation, overheads, leverage and accruals As ofThe filing date of the statements below, for FY2025. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tabForm40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab
	n/a	FY2025	Mar 31, 2026
n/a The nine signals need complete filed accounts for two consecutive years and at least one input is not on file.
FormulaOne point each for: positive return on assets, positive operating cash flow, rising return on assets, operating cash flow above net income, falling leverage, rising current ratio, no new shares issued, rising gross margin, rising asset turnover. As ofThe filing date of the statements below, for FY2025. Form40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itIncome statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tabForm40-FFiledMar 31, 2026PeriodFY2025Accession0001376474-26-000257What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001376474-26-000257, leaves this page and opens in a new tab

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 3 filed fiscal years on record, FY2023 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 fiscal years, FY2016 to FY2025. 3 read from the annual reports BioHarvest Sciences Inc. Common Stock filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in USD, as reported.

BioHarvest Sciences Inc. Common Stock: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
Year	Revenue	Operating income	Net income	EPS, diluted	Free cash flow	Operating margin	Return on equity	Filing
FY2025	34.5M	-5.6M	-11.1M	n/a	-9.6M	-16.2%	n/a	40-F, Mar 31, 20260001376474-26-000257
FY2024	25.2M	-7.0M	-12.9M	n/a	-9.5M	-27.8%	n/a	40-F, Mar 31, 20250001376474-25-000299
FY2023	12.7M	-10.0M	-12.6M	n/a	-10.0M	-78.7%	n/a	40-F, Mar 31, 20250001376474-25-000299
FY2022	5.5M	-10.6M	-11.2M	-0.70	-10.5M	-193.0%	n/m	Market data, supplied Oct 15, 2026accession n/a
FY2021	2.1M	-8.5M	-9.8M	-0.70	-8.4M	-403.9%	-344.2%	Market data, supplied Oct 15, 2026accession n/a
FY2020	396.0K	-6.2M	-6.6M	-0.70	-4.0M	-1557.1%	n/m	Market data, supplied Oct 15, 2026accession n/a
FY2019	218.0K	-2.3M	-5.3M	-1.75	-2.4M	-1059.6%	n/m	Market data, supplied Oct 15, 2026accession n/a
FY2018	n/a	-4.4M	-5.1M	-2.34	n/a	n/a	n/a	Market data, supplied Oct 15, 2026accession n/a
FY2017	n/a	-5.0K	-5.0K	-0.21	-1.0K	n/a	-1.8%	Market data, supplied Oct 15, 2026accession n/a
FY2016	n/a	-96.6K	-103.4K	-0.27	-74.6K	n/a	n/m	Market data, supplied Oct 15, 2026accession n/a

Revenue, compound annual growth FY2019 to FY2025: 132.6%
Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
Earnings per share: Earnings per share was not positive in both 2016 and 2022, so a compound rate across the window is not defined. Both figures are in the table.
Free cash flow: Free cash flow was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

BioHarvest Sciences Inc. Common Stock: accounting screens and published tests, each with its source
Figure	Value, source and document
Beneish M-score Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Piotroski F-score Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 40-F, filed Mar 31, 2026, 0001376474-26-000257
Named tests met	0 of 30 Computed
Beta Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 8 not met, 22 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)

Meets: None of the named tests.
Does not: Large cap, low P/E; High yield, low payout; Dividends and buybacks; Near the 52-week low; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Cash-flow yield and ROIC
Not measured: Defensive investor (Benjamin Graham); Deep value; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; Low beta, profitable; ROIC at or above WACC; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); High returns, low debt; Book or below, low debt (Walter Schloss); Cash-covered dividend; Tangible book or below; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.

Figures we could not read(28)

Current Ratio: No annual statement of this kind is on file for this fiscal year.
Debt to Equity: No annual statement of this kind is on file for this fiscal year.
Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
P/B Ratio: We do not hold this figure for this company, so there is nothing to show.
Piotroski F-Score: We do not hold this figure for this company, so there is nothing to show.
P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
Return on Invested Capital: No annual statement of this kind is on file for this fiscal year.
Altman Z-Score: We do not hold this figure for this company, so there is nothing to show.
Beneish M-Score: We do not hold this figure for this company, so there is nothing to show.
PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
Return on Equity: No annual statement of this kind is on file for this fiscal year.
Asset Turnover: We do not hold this figure for this company, so there is nothing to show.
EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
Beta: We do not hold this figure for this company, so there is nothing to show.
ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
Price To Ncav: We do not hold this figure for this company, so there is nothing to show.
Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
Return Tangible: We do not hold this figure for this company, so there is nothing to show.
Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
Dividend Streak: We do not hold this figure for this company, so there is nothing to show.
Price Tangible Book: We do not hold this figure for this company, so there is nothing to show.
Tangible Equity Ratio: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

Value it in the DCF workbench

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

What this cannot tell you

28 figures could not be read on this company, among them Current Ratio, Debt to Equity, Positive Earnings Streak. Each blank in the table above names the rest, with its reason. 22 named tests come back incomplete because of them, which is neither met nor missed.
We hold 3 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolio How this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Four questions, at a glance

Quality

Financial strength

Valuation

Cash generation

Revenue and net income, by fiscal year

The reading, in brief

Financial health

Valuation

Companies like BioHarvest Sciences Inc. Common Stock

The filed figures

Ten years of filed figures

The named tests

What this cannot tell you

Margin Notes